RARE - Ultragenyx Pharmaceutical GAAP EPS of -$2.25 misses by $0.15 revenue of $108.3M beats by $3.31M

2023-08-03 16:52:06 ET

• Ultragenyx Pharmaceutical press release ( NASDAQ: RARE ): Q2 GAAP EPS of -$2.25 misses by $0.15 .
• Revenue of $108.3M (+21.2% Y/Y) beats by $3.31M .

• For the full year 2023, the company expects:

  • Total revenue in the range of $425 million to $450 million vs $437.01M consensus
  • Crysvita revenue in the range of $325 million to $340 million. This includes all regions where Ultragenyx will recognize revenue, including the royalties in Europe, which have been ongoing, and the royalties in North America, which began in April 2023.
  • Dojolvi revenue in the range of $65 million to $75 million
  • Net Cash Used in Operations to be around $400 million

For further details see: